3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
238
Carcinoma, Non-Small-Cell Lung
205
Prostatic Neoplasms
137
Lung Neoplasms
96
Stomach Neoplasms
85
Head and Neck Neoplasms
58
Squamous Cell Carcinoma of Head and Neck
57
Neoplasms
42
Neoplasm Metastasis
39
Esophageal Neoplasms
36
Ovarian Neoplasms
29
Pancreatic Neoplasms
27
Sarcoma
19
Urinary Bladder Neoplasms
18
Adenocarcinoma of Lung
18
Carcinoma, Squamous Cell
17
Triple Negative Breast Neoplasms
15
Nasopharyngeal Carcinoma
14
Adenocarcinoma
14
Carcinoma, Ovarian Epithelial
13
Adenocarcinoma Of Esophagus
13
Recurrence
12
Inflammatory Breast Neoplasms
10
Carcinoma, Transitional Cell
10
Breast Neoplasms, Male
10
Esophageal Squamous Cell Carcinoma
9
Laryngeal Neoplasms
8
Uterine Cervical Neoplasms
7
Nasopharyngeal Neoplasms
7
Leiomyosarcoma
7
Interventions
enzalutamide
4
abiraterone
2
sapanisertib
1
onvansertib
1
inavolisib
1
abemaciclib
1
Prednisone
1
Docetaxel
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Castration-Resistant Prostate Cancer
×
Docetaxel
×
Clear all
NCT07287150
2026-05-06
InavoPC
Hoffmann-La Roche
Phase 2
Recruiting
100 enrolled